Roche Diagnostics showcases science-driven leadership and innovation at ADLM 2025
Roche Diagnostics (OTCQX: RHHBY) will showcase its diagnostic innovations at the 2025 ADLM Scientific Meeting and Clinical Lab Expo in Chicago from July 28-31. The company will highlight its comprehensive diagnostic solutions including the cobas® portfolio, featuring integrated platforms for clinical chemistry and molecular diagnostics.
Key presentations include workshops on cardiovascular risk assessment focusing on Lipoprotein(a) testing and cervical cancer screening innovations. Notable product showcases include the future cobas® Mass Spec solution, cobas® pure integrated solutions, and advanced molecular diagnostic systems like the cobas® liat and eplex systems.
The company emphasizes its commitment to AI-powered digital transformation, laboratory efficiency, and expanding healthcare partnerships through its navify® digital solutions platform.
Roche Diagnostics (OTCQX: RHHBY) presenterà le sue innovazioni diagnostiche al 2025 ADLM Scientific Meeting and Clinical Lab Expo che si terrà a Chicago dal 28 al 31 luglio. L'azienda metterà in evidenza le sue soluzioni diagnostiche complete, incluso il portafoglio cobas®, con piattaforme integrate per la chimica clinica e la diagnostica molecolare.
Le presentazioni principali comprenderanno workshop sulla valutazione del rischio cardiovascolare con particolare attenzione al test della Lipoproteina(a) e sulle innovazioni nello screening del cancro cervicale. Tra i prodotti in evidenza ci saranno la futura soluzione cobas® Mass Spec, le soluzioni integrate cobas® pure e sistemi avanzati di diagnostica molecolare come i sistemi cobas® liat ed eplex.
L'azienda sottolinea il suo impegno nella trasformazione digitale potenziata dall'IA, nell'efficienza di laboratorio e nell'espansione delle collaborazioni sanitarie attraverso la piattaforma digitale navify®.
Roche Diagnostics (OTCQX: RHHBY) presentará sus innovaciones diagnósticas en el 2025 ADLM Scientific Meeting and Clinical Lab Expo en Chicago del 28 al 31 de julio. La compañía destacará sus soluciones diagnósticas integrales, incluyendo el portafolio cobas®, que cuenta con plataformas integradas para química clínica y diagnóstico molecular.
Las presentaciones clave incluyen talleres sobre evaluación del riesgo cardiovascular centrados en la prueba de Lipoproteína(a) y novedades en el cribado del cáncer cervical. Entre los productos destacados se encuentran la futura solución cobas® Mass Spec, las soluciones integradas cobas® pure y sistemas avanzados de diagnóstico molecular como los sistemas cobas® liat y eplex.
La empresa enfatiza su compromiso con la transformación digital impulsada por IA, la eficiencia en laboratorio y la ampliación de las colaboraciones en salud a través de su plataforma digital navify®.
로슈 다이아그노스틱스(OTCQX: RHHBY)는 7월 28일부터 31일까지 시카고에서 열리는 2025 ADLM 과학 회의 및 임상 실험실 박람회에서 진단 혁신을 선보일 예정입니다. 회사는 임상 화학 및 분자 진단을 위한 통합 플랫폼을 포함한 코바스® 포트폴리오 등 종합 진단 솔루션을 강조할 것입니다.
주요 발표로는 지질단백질(a) 검사에 중점을 둔 심혈관 위험 평가 워크숍과 자궁경부암 선별 혁신이 포함됩니다. 주목할 만한 제품으로는 미래형 코바스® 질량분석 솔루션, 코바스® 퓨어 통합 솔루션, 코바스® liat 및 eplex와 같은 고급 분자 진단 시스템이 있습니다.
회사는 AI 기반 디지털 전환, 실험실 효율성, navify® 디지털 솔루션 플랫폼을 통한 의료 파트너십 확장에 대한 의지를 강조합니다.
Roche Diagnostics (OTCQX : RHHBY) présentera ses innovations diagnostiques lors du 2025 ADLM Scientific Meeting and Clinical Lab Expo à Chicago, du 28 au 31 juillet. L'entreprise mettra en avant ses solutions diagnostiques complètes, incluant le portefeuille cobas®, avec des plateformes intégrées pour la chimie clinique et le diagnostic moléculaire.
Les présentations clés comprendront des ateliers sur l'évaluation du risque cardiovasculaire axés sur le test de Lipoprotéine(a) et les innovations dans le dépistage du cancer du col de l'utérus. Parmi les produits phares figurent la future solution cobas® Mass Spec, les solutions intégrées cobas® pure et des systèmes avancés de diagnostic moléculaire tels que les systèmes cobas® liat et eplex.
L'entreprise souligne son engagement envers la transformation numérique propulsée par l'IA, l'efficacité des laboratoires et l'expansion des partenariats en santé via sa plateforme numérique navify®.
Roche Diagnostics (OTCQX: RHHBY) wird seine diagnostischen Innovationen auf dem 2025 ADLM Scientific Meeting and Clinical Lab Expo in Chicago vom 28. bis 31. Juli präsentieren. Das Unternehmen stellt seine umfassenden diagnostischen Lösungen vor, darunter das cobas®-Portfolio mit integrierten Plattformen für klinische Chemie und molekulare Diagnostik.
Zu den Hauptvorträgen gehören Workshops zur Bewertung des kardiovaskulären Risikos mit Schwerpunkt auf Lipoprotein(a)-Tests sowie Innovationen im Zervixkarzinom-Screening. Hervorzuhebende Produkte sind die zukünftige cobas® Mass Spec-Lösung, cobas® pure integrierte Lösungen und fortschrittliche molekulare Diagnostiksysteme wie die cobas® liat- und eplex-Systeme.
Das Unternehmen betont sein Engagement für die KI-gestützte digitale Transformation, die Effizienz im Labor und den Ausbau von Gesundheitskooperationen durch seine digitale Plattform navify®.
- None.
- None.
Lead With Us -- a promise for innovative partnerships, better insights, faster support, and improved healthcare outcomes.
In an era of rapid scientific advancement, Roche harnesses the full force of innovation to deliver deeper insights, faster support, and better outcomes. By expanding partnerships across the healthcare ecosystem, Roche amplifies its reach — connecting with more patients and labs, in more settings, with greater efficiency.
"Innovation, integration and partnership are the cornerstones of Roche's vision for the future of diagnostics," said Brad Moore, president and CEO of Roche Diagnostics North America. "Our ADLM presence is about more than technology — it's about connecting science to people, delivering value where it matters most and working together to shape the next era of care."
From AI-powered digital transformation to proven assay performance, Roche empowers laboratories to achieve lasting success through evidence-based innovation and a focus on patient-centered care.
Roche's presence at ADLM reflects a holistic approach to healthcare innovation, one that integrates powerful science with intelligent technologies. Visit Roche Diagnostics at Booth 1902 to explore how our solutions bring science to life, simplify operations and elevate diagnostic excellence for patients worldwide.
With the largest diagnostics installed base worldwide, Roche provides unrivaled ability to scale access to testing at speed for those who need it most. The cobas® reagent portfolio offers the broadest menu on an integrated platform and includes the Elecsys® Alzheimer's cerebrospinal fluid (CSF) assays, aiming to more effectively detect amyloid pathology and support an Alzheimer's disease diagnosis.
Roche will also present its full array of navify® digital solutions, which securely integrate data across care settings, connecting the healthcare community and accelerating access to innovation and insights. Our digital solutions enable confident healthcare decisions and help you drive operational, clinical and financial value.
Join Our Expert-Led Medical Workshops
As part of its scientific programming, Roche is hosting two dynamic workshops led by industry experts:
- Cardiovascular Risk Assessment and Lipoprotein(a): Closing Gaps in ASCVD Prevention
Lipoprotein(a), or Lp(a), is a genetically inherited, independent risk factor for Atherosclerotic Cardiovascular Disease (ASCVD), yet remains under-recognized in routine clinical assessment. This workshop will explore critical gaps in awareness, testing and risk stratification related to Lp(a), with a focus on identifying and managing people with high risk for cardiovascular disease.
Attendees will:
- Gain a deeper understanding of Lp(a)'s role in ASCVD and its implications for personalized care
- Learn about Roche's FDA-cleared, commercially available Lp(a) Molarity Assay, designed to deliver standardized, clinically actionable results
- Explore how emerging Lp(a)-lowering therapies and diagnostics can support more tailored cardiovascular risk management strategies
- Innovations in Cervical-Cancer Screening and Diagnosis
Cervical cancer remains one of the most preventable yet deadly cancers — particularly in underserved populations. This session will explore the latest advancements in cervical-cancer screening and diagnosis, including self-collection methods, updated clinical guidelines, and the evolving role of technologies such as extended HPV genotyping and home-based testing. Expert speakers will share insights on how these developments can increase awareness and expand access to regular screening across diverse populations.
Attendees will:- Review the current technology landscape for cervical-cancer screening and diagnosis
- Explore updates to ASCCP and USPSTF guidelines and their implications for clinical practice
- Consider strategies to expand access for under- or never-screened populations
- Examine the potential role of home-collection in improving screening rates, including challenges to implementation and follow-up care
- Discuss the clinical utility and relevance of HPV extended genotyping
These sessions reflect Roche's belief that science holds its true power when it is accessible, and that collaboration matters most when it drives real transformation.
Focusing on key attributes of science-based leadership, operational simplicity and patient-centric partnership, Roche will feature its newest innovations in-booth at ADLM, including:
- The future cobas® Mass Spec solution* is designed to be a total end-to-end solution for clinical mass spectrometry testing with the goal of seamless integration into the routine laboratory.
- The cobas® pure integrated solutions combine clinical chemistry, immunoassay and Ion-Selective Electrode (ISE) diagnostic testing on a single platform for low- to mid-volume testing needs.
- The CCM Vertical is a flexible, modular system that utilizes lab space effectively and seamlessly integrates into the existing cobas® connection modules.
- The cobas® liat system brings gold-standard PCR technology to the point of care, providing results within 20 minutes across a growing test menu of CLIA-waived multiplex and singleplex assays, with a focus on respiratory and sexual health diagnostics.
- The cobas® eplex system, a rapid, syndromic molecular diagnostic solution, offers test panels for respiratory and bloodstream infections, integrating the entire process from order to report.
- The cobas® 6800/8800 Systems v2** are designed to enhance usability, streamline efficiency and support more intuitive workflows. Based on customer feedback and real-world usability testing, this update introduces improvements aimed at optimizing the user experience, availability as updated software for current systems as well as a new system model.
- The LightCycler® PRO is a qPCR system designed to deliver accuracy and flexibility to research in and clinical diagnostic laboratories with an improved user experience.
- The VENTANA® DP 600 slide scanner is a computer and imaging based device that has the capability to scan stained tissue specimens on glass slides, and digitize, compress, store, retrieve, and view digitized images of tissue slide specimens on glass slides.
At Roche, we invest more, partner more and push boundaries more — because patients deserve nothing less. Together, we're not just advancing diagnostics — we're transforming it.
For more information about Roche's participation at ADLM 2025, visit ADLM.roche.com.
*Not currently for sale in
**The cobas® 6800/8800 System Software 2.0 and new models for the system are not yet available in the
About Roche
Founded in 1896 in
For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For Further Information
To find more information on Roche and images for media use, please visit the Roche Media Library.
Roche Diagnostics
us.mediarelations@roche.com
Onsite at ADLM:
Jen Dial
jen.dial@roche.com
1-463-867-0232
Amy Lynn
amy.lynn@roche.com
1-317-750-7811
Downloads
cobas® Mass Spec solution image
cobas® Connection Module (CCM) Vertical image
cobas® liat system image
cobas® pure integrated solutions image
cobas® eplex system image
cobas® 5800 image LightCycler® PRO image
HPV self-collection animation
View original content to download multimedia:https://www.prnewswire.com/news-releases/roche-diagnostics-showcases-science-driven-leadership-and-innovation-at-adlm-2025-302512634.html
SOURCE Roche Diagnostics
FAQ
When and where is Roche Diagnostics presenting at ADLM 2025?
What new diagnostic products will Roche showcase at ADLM 2025?
What topics will Roche's expert-led workshops cover at ADLM 2025?
What digital solutions is Roche presenting at ADLM 2025?
What diagnostic testing capabilities does the cobas® pure integrated solutions offer?
